Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016

  • ID: 3753845
  • Report
  • 70 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akebia Therapeutics, Inc.
  • Bayer AG
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc.
  • Merck & Co., Inc.
  • MORE
Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016

Summary

‘Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016’, provides in depth analysis on Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted pipeline therapeutics.

The report provides comprehensive information on the Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.)
- The report reviews Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akebia Therapeutics, Inc.
  • Bayer AG
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc.
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) Overview

Therapeutics Development

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Products under Development by Stage of Development

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Products under Development by Therapy Area

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Products under Development by Indication

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Pipeline Products Glance

Late Stage Products

Early Stage Products

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Products under Development by Companies

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Companies Involved in Therapeutics Development

Akebia Therapeutics, Inc.

Bayer AG

Daiichi Sankyo Company, Limited

FibroGen, Inc.

GlaxoSmithKline Plc

Japan Tobacco Inc.

Merck & Co., Inc.

Sigmoid Pharma Limited

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Drug Profiles

AKB-6899 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daprodustat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyloxalylglycine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1093 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-2216 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-4497 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-6874 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-8205 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTZ-951 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molidustat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roxadustat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Prolyl Hydroxylase for Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadadustat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Dormant Projects

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) – Featured News & Press Releases

May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat

Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings

Apr 20, 2016: Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis

Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat

Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease

Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program

Nov 07, 2015: Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting

Nov 03, 2015: FibroGen to Present Roxadustat Clinical Data in Four Presentations at American Society of Nephrology - Kidney Week 2015

Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting

Oct 22, 2015: Phase 2 Data For Investigational Orally Active Hif-Phi Roxadustat Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality

Oct 06, 2015: Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program

Sep 08, 2015: Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease

Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia

May 29, 2015: Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease at the 52nd ERA-EDTA Congress

May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Akebia Therapeutics, Inc., H1 2016

Pipeline by Bayer AG, H1 2016

Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Pipeline by FibroGen, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Japan Tobacco Inc., H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Sigmoid Pharma Limited, H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Akebia Therapeutics, Inc.
Bayer AG
Daiichi Sankyo Company, Limited
FibroGen, Inc.
GlaxoSmithKline Plc
Japan Tobacco Inc.
Merck & Co., Inc.
Sigmoid Pharma Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll